Key Points
- CEO Martine Rothblatt sold 9,500 UTHR shares on March 16 at an average price of $533.90 for proceeds of $5.07M, reducing her ownership by 19% to 40,513 shares (worth about $21.63M).
- United Therapeutics posted quarterly EPS of $7.70 (beats estimates) but revenue of $790.2M missed consensus; analysts hold a Moderate Buy consensus with an average price target of $548.09.
United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the firm's stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $533.90, for a total value of $5,072,050.00. Following the sale, the chief executive officer owned 40,513 shares of the company's stock, valued at $21,629,890.70. The trade was a 19.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.
United Therapeutics Price Performance
NASDAQ:UTHR opened at $540.02 on Wednesday. The stock has a market cap of $23.67 billion, a PE ratio of 19.36, a price-to-earnings-growth ratio of 1.92 and a beta of 0.84. United Therapeutics Corporation has a fifty-two week low of $266.98 and a fifty-two week high of $548.12. The stock's 50-day moving average is $488.31 and its two-hundred day moving average is $465.54.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $6.78 by $0.92. United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. The business had revenue of $790.20 million during the quarter, compared to analyst estimates of $814.80 million. During the same period in the prior year, the firm earned $6.19 earnings per share. The firm's revenue was up 7.4% compared to the same quarter last year. On average, equities research analysts anticipate that United Therapeutics Corporation will post 24.48 earnings per share for the current year.
Analyst Upgrades and Downgrades
A number of equities research analysts have issued reports on the stock. Jefferies Financial Group reissued a "buy" rating on shares of United Therapeutics in a research note on Monday, March 2nd. Weiss Ratings reiterated a "buy (b)" rating on shares of United Therapeutics in a report on Monday, December 29th. Cantor Fitzgerald lifted their price objective on United Therapeutics from $525.00 to $625.00 and gave the company an "overweight" rating in a research report on Thursday, March 12th. Wells Fargo & Company boosted their target price on United Therapeutics from $423.00 to $466.00 and gave the company an "equal weight" rating in a research note on Thursday, February 26th. Finally, TD Cowen upped their target price on United Therapeutics from $525.00 to $575.00 and gave the stock a "buy" rating in a research report on Wednesday, February 25th. Nine analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $548.09.
Get Our Latest Stock Analysis on UTHR
Institutional Inflows and Outflows
Institutional investors have recently made changes to their positions in the stock. AXQ Capital LP lifted its stake in shares of United Therapeutics by 495.4% in the second quarter. AXQ Capital LP now owns 3,888 shares of the biotechnology company's stock worth $1,117,000 after buying an additional 3,235 shares during the last quarter. AE Wealth Management LLC grew its stake in United Therapeutics by 396.3% in the 3rd quarter. AE Wealth Management LLC now owns 4,288 shares of the biotechnology company's stock valued at $1,798,000 after buying an additional 3,424 shares during the last quarter. Great Lakes Advisors LLC raised its holdings in United Therapeutics by 194.7% in the 3rd quarter. Great Lakes Advisors LLC now owns 4,503 shares of the biotechnology company's stock worth $1,888,000 after acquiring an additional 2,975 shares during the period. Optimize Financial Inc bought a new position in United Therapeutics in the 3rd quarter worth $444,000. Finally, Simplify Asset Management Inc. acquired a new position in United Therapeutics during the 3rd quarter worth $8,351,000. 94.08% of the stock is owned by institutional investors.
United Therapeutics Company Profile
(
Get Free Report)
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
